Expression of Concern
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 11, Issue 15 pp 5848—5863
Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma
Figure 6. Proposed model of osteosarcoma growth suppression upon dual treatment with sodium cantharidate and erlotinib. Combined treatment with sodium cantharidate (Sc) and erlotinib impedes erlotinib-induced activation of STAT3 and signaling through the STAT3/Bcl-2/MMP2 axis, leading to enhanced growth suppression in osteosarcoma.